Vestmark Advisory Solutions Inc. Buys 35,721 Shares of Boston Scientific Corporation $BSX

Key Points

• Vestmark Advisory Solutions Inc. increased its stake in Boston Scientific Corporation by 83.2%, acquiring 35,721 additional shares during the first quarter, bringing their total to 78,657 shares valued at approximately $7.93 million.
• Boston Scientific reported a 22.8% year-over-year increase in revenue to $5.06 billion for the most recent quarter, with earnings per share beating estimates at $0.75.
• Analysts have a consensus rating of "Buy" for Boston Scientific, with target prices increasing, including an upgrade from Robert W. Baird from $117 to $123.

Vestmark Advisory Solutions Inc. grew its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 83.2% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 78,657 shares of the medical equipment provider's stock after acquiring an additional 35,721 shares during the period. Vestmark Advisory Solutions Inc.'s holdings in Boston Scientific were worth $7,935,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. NS Partners Ltd increased its position in shares of Boston Scientific by 1.6% during the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock valued at $37,143,000 after buying an additional 5,704 shares during the period. Bank Pictet & Cie Europe AG raised its position in Boston Scientific by 40.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after purchasing an additional 21,173 shares during the period. Oppenheimer & Co. Inc. raised its position in Boston Scientific by 18.8% in the 1st quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock worth $3,987,000 after purchasing an additional 6,264 shares during the period. Segall Bryant & Hamill LLC purchased a new position in Boston Scientific in the 1st quarter worth $8,234,000. Finally, Blue Trust Inc. raised its position in Boston Scientific by 13.0% in the 1st quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock worth $504,000 after purchasing an additional 575 shares during the period. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares of the company's stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Michael F. Mahoney sold 164,443 shares of Boston Scientific stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the completion of the transaction, the chief executive officer directly owned 1,476,882 shares of the company's stock, valued at $153,137,894.58. The trade was a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 345,029 shares of company stock worth $35,976,603 in the last 90 days. 0.50% of the stock is owned by company insiders.

Boston Scientific Price Performance

Shares of BSX stock traded up $0.4040 on Tuesday, hitting $103.4540. 2,934,960 shares of the stock traded hands, compared to its average volume of 7,561,748. The firm has a market cap of $153.29 billion, a price-to-earnings ratio of 61.61, a PEG ratio of 2.48 and a beta of 0.66. Boston Scientific Corporation has a 52 week low of $78.08 and a 52 week high of $108.94. The firm has a 50 day simple moving average of $103.62 and a two-hundred day simple moving average of $102.09. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's revenue was up 22.8% on a year-over-year basis. During the same period last year, the firm earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on BSX shares. Erste Group Bank upgraded shares of Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Raymond James Financial increased their target price on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Wells Fargo & Company upped their target price on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Finally, Robert W. Baird upped their target price on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $117.50.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.